Dr. Khodadoust is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
875 Blake Wilbur Dr
Palo Alto, CA 94304Phone+1 650-498-6000Fax+1 650-724-1231- Is this information wrong?
Education & Training
- Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 2012 - 2015
- University of Michigan Medical SchoolClass of 2010
Certifications & Licensure
- CA State Medical License 2011 - 2025
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma Start of enrollment: 2016 Nov 07
- Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment Start of enrollment: 2021 Apr 06
Publications & Presentations
PubMed
- 585 citationsEarly Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA ProfilingAadel A. Chaudhuri, Jacob J. Chabon, Alexander F. Lovejoy, Aaron M. Newman, Henning Stehr
Cancer Discovery. 2017-12-01 - 272 citationsCirculating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell LymphomaDavid M. Kurtz, Florian Scherer, Michael C. Jin, Joanne Soo, Alexander F.M. Craig
Journal of Clinical Oncology. 2018-08-20 - 2047 citationsDetermining cell type abundance and expression from bulk tissues with digital cytometry.Aaron M. Newman, Chloé B. Steen, Chih Long Liu, Andrew J. Gentles, Aadel A. Chaudhuri
Nature Biotechnology. 2019-05-06
Journal Articles
- Targeted Killing of TNFR2-Expressing Tumor Cells and Tregs by TNFR2 Antagonistic Antibodies in Advanced Sézary SyndromeD L Faustman, Y H Kim, M Khodadoust, Nature
- Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results of the CITN Multicenter Phase 2 StudyMichael S Khodadoust, Pierluigi Porcu, Francine Foss, Andrei R Shustov, Satish Shanbhag, Lubomir Sokol, Steven M Horwitz, Elad Sharon, European Journal of Cancer
- IPH4102 in relapsed/refractory Cutaneous T Cell Lymphoma (CTCL): Results of the First-in-Human Multicenter Phase 1 StudyPierluigi Porcu, Basem William, Michael Khodadoust, European Journal of Cancer
Abstracts/Posters
- Maria-I: A Deep-Learning Approach for Accurate Prediction of MHC Class I Tumor Neoantigen PresentationMichael S. Khodadoust, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma CellsMichael S. Khodadoust, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell LymphomaMichael S. Khodadoust, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Authored Content
- Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results of the CITN Multicenter Phase 2 StudyAugust 2018
- Profiling Tumor Infiltrating Immune Cells with CIBERSORTJanuary 2018
Press Mentions
- Stanford Coach’s Quest to Save His Brother: ‘God, I Hope This Works’November 12th, 2020
- ‘Liquid Biopsy’ Predicts Lymphoma Therapy Success Within DaysAugust 20th, 2018
- New Computational Tool Enables Powerful Molecular Analysis of Biomedical Tissue SamplesMay 8th, 2019
Hospital Affiliations
- Stanford Health CarePalo Alto, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: